Radiolabeled Antibodies Against Mullerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer
Conclusion: Radiolabeled 16F12 could represent a new theranostic tool for small-volume ovarian peritoneal carcinomatosis. Specifically, 213Bi-16F12–based BIP-RIT could be proposed to selected patients as an alternative adjuvant treatment immediately after cytoreductive surgery. An anti-MISRII mAb is currently being used in a first-in-human study, thus making radiolabeled anti-MISRII mAbs a realistic theranostic option for the clinic.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Deshayes, E., Ladjohounlou, R., Le Fur, P., Pichard, A., Lozza, C., Boudousq, V., Sevestre, S., Jarlier, M., Kashani, R., Koch, J., Sosabowski, J., Foster, J., Chouin, N., Bruchertseifer, F., Morgenstern, A., Kotzki, P.-O., Navarro-Teulon, I., Pouget, J.- Tags: Basic Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Endometrial Cancer | Hematology | Nuclear Medicine | Ovarian Cancer | Ovaries | Peritoneal Cancer | SPECT | Study | Toxicology